{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.99","upperLimit":"14.3","value":"11.4"},{"groupId":"OG001","lowerLimit":"16.4","upperLimit":"28.9","value":"22.0"},{"groupId":"OG002","lowerLimit":"20.0","upperLimit":"31.2","value":"25.3"},{"groupId":"OG003","lowerLimit":"19.8","upperLimit":"42.9","value":"32.9"},{"groupId":"OG004","lowerLimit":"6.32","upperLimit":"67.7","value":"37.5"},{"groupId":"OG005","lowerLimit":"45.1","upperLimit":"74.4","value":"54.2"},{"groupId":"OG006","lowerLimit":"47.1","upperLimit":"75.5","value":"61.9"},{"groupId":"OG007","lowerLimit":"39.9","upperLimit":"80.9","value":"55.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.26","upperLimit":"15.4","value":"11.5"},{"groupId":"OG001","lowerLimit":"20.6","upperLimit":"44.6","value":"29.3"},{"groupId":"OG002","lowerLimit":"26.4","upperLimit":"39.0","value":"31.0"},{"groupId":"OG003","lowerLimit":"24.0","upperLimit":"51.5","value":"38.5"},{"groupId":"OG004","lowerLimit":"29.0","upperLimit":"53.8","value":"40.1"},{"groupId":"OG005","lowerLimit":"51.2","upperLimit":"84.7","value":"60.8"},{"groupId":"OG006","lowerLimit":"67.4","upperLimit":"89.9","value":"78.7"},{"groupId":"OG007","lowerLimit":"46.6","upperLimit":"89.9","value":"73.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.09","upperLimit":"14.5","value":"11.9"},{"groupId":"OG001","lowerLimit":"20.4","upperLimit":"30.5","value":"23.9"},{"groupId":"OG002","lowerLimit":"21.4","upperLimit":"29.8","value":"25.3"},{"groupId":"OG003","lowerLimit":"19.3","upperLimit":"47.2","value":"34.7"},{"groupId":"OG004","lowerLimit":"8.72","upperLimit":"75.8","value":"40.2"},{"groupId":"OG005","lowerLimit":"49.6","upperLimit":"55.5","value":"52.4"},{"groupId":"OG006","lowerLimit":"50.4","upperLimit":"84.9","value":"67.7"},{"groupId":"OG007","lowerLimit":"33.7","upperLimit":"73.8","value":"52.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.84","upperLimit":"13.5","value":"11.9"},{"groupId":"OG001","lowerLimit":"22.5","upperLimit":"51.8","value":"34.6"},{"groupId":"OG002","lowerLimit":"28.9","upperLimit":"40.5","value":"33.2"},{"groupId":"OG003","lowerLimit":"25.0","upperLimit":"56.2","value":"41.6"},{"groupId":"OG004","lowerLimit":"34.6","upperLimit":"63.9","value":"45.3"},{"groupId":"OG005","lowerLimit":"55.5","upperLimit":"72.4","value":"63.4"},{"groupId":"OG006","lowerLimit":"50.2","upperLimit":"109","value":"79.6"},{"groupId":"OG007","lowerLimit":"39.0","upperLimit":"77.2","value":"62.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.000501","value":"0.000312"},{"groupId":"OG003","lowerLimit":"0.000445","upperLimit":"0.000693","value":"0.000549"},{"groupId":"OG004","lowerLimit":"0.000568","upperLimit":"0.00210","value":"0.00131"},{"groupId":"OG005","lowerLimit":"0.000967","upperLimit":"0.00192","value":"0.00141"},{"groupId":"OG006","lowerLimit":"0.00123","upperLimit":"0.00201","value":"0.00155"},{"groupId":"OG007","lowerLimit":"0.000924","upperLimit":"0.00210","value":"0.00149"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"DM1 after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"0.00","value":"0.00"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"0.000356","value":"0.000119"},{"groupId":"OG002","lowerLimit":"0.000297","upperLimit":"0.000590","value":"0.000414"},{"groupId":"OG003","lowerLimit":"0.000423","upperLimit":"0.000913","value":"0.000654"},{"groupId":"OG004","lowerLimit":"0.000658","upperLimit":"0.00121","value":"0.000872"},{"groupId":"OG005","lowerLimit":"0.00141","upperLimit":"0.00264","value":"0.00172"},{"groupId":"OG006","lowerLimit":"0.00151","upperLimit":"0.00170","value":"0.00161"},{"groupId":"OG007","lowerLimit":"0.00140","upperLimit":"0.00242","value":"0.00177"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"8"}],"units":"Participants"}],"title":"DM1 after Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"Cmax of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured. DM1 is a semi-synthetic derivative of the ansamycin antibiotic, maytansine conjugated to the non-cleavable linker 4-\\[N-maleimidomethyl\\] cyclohexane-1-carboxylate conjugated to lysine residues in the antibody (MCC).","dispersionType":"Full Range","groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"All participants in Dose Expansion who had prior treatment or no prior treatment with a CD38-targeting antibody were administered the MTD of AMG 224 identified in the dose escalation as 3 mg/kg. AMG 224 was administered as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG007","title":"Dose Expansion: AMG 224 3 mg/kg"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated.","reportingStatus":"POSTED","timeFrame":"AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, end of infusion (EOI), 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)","title":"Maximum Observed Concentration (Cmax) of AMG 224 Conjugated Antibody, Total Anti-B-cell Maturation Antigen (Anti-BCMA) Antibody, and Total Unconjugated DM1","type":"SECONDARY","unitOfMeasure":"µg/mL"}